PulseAugur
EN
LIVE 11:34:39
中文(ZH) 先声药业与美国薛定谔公司达成全球创新药研发战略合作

Sino Biopharmaceutical and Schrödinger Ink Global Drug Discovery Deal

Sino Biopharmaceutical Limited has entered into a global strategic collaboration with Schrödinger Inc. to advance the discovery and development of innovative drugs. This partnership will focus on addressing unmet clinical needs, with Schrödinger eligible for milestone payments and tiered royalties based on the success of the collaborative projects. The agreement aims to leverage both companies' expertise in drug discovery and development. AI

IMPACT This partnership leverages AI in drug discovery, potentially accelerating the development of new treatments.

RANK_REASON Partnership between two companies for drug discovery.

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Sino Biopharmaceutical and Schrödinger Ink Global Drug Discovery Deal

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Simcere Pharmaceutical Group and Schrödinger Inc. Reach Strategic Cooperation on Global Innovative Drug R&D

    36氪获悉,7月10日,先声药业宣布,已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。根据协议,薛定谔公司有权获得合作项目在发现、开发及商业化阶段的里程碑付款,以及基于产品净销售额的阶梯式特许权使用费。双方将聚焦未满足的临床需求,共同���进创新药物研发。